Beam Therapeutics Inc.
BEAM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745999
In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 277 institutions reported holding it in 13F filings for Q2 2026, worth $4.10B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $12.2M in total
- 4
- 13F holdersQ2 2026, +27 vs. previous quarter
- 277
- 13F valueReported value at the end of Q2 2026
- $4.10B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Superinvestors holding BEAM, Q2 2026
2 superinvestors report holding Beam Therapeutics Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
2.3%
Beam Therapeutics Inc.'s share of the portfolio
- Shares
- 10,234,862
- Value
- $351.3M
Duquesne Family Office
Stanley Druckenmiller
0.1%
Beam Therapeutics Inc.'s share of the portfolio
- Shares
- 153,600
- Value
- $5.27M
Latest insider trades
Open-market purchases and sales by Beam Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 (view filing)4:05 PM ET | Jul 27 | 2 days | Simon AmyChief Medical Officer | SSale | −16.7K | $25.74 | −$429.0K | −16.3%85.7K after | 10b5-1 |
| Jul 2, 2026 (view filing)4:05 PM ET | Jun 30 | 2 days | Simon AmyChief Medical Officer | SSale | −373 | $34.73 | −$13.0K | −0.4%102.4K after | 10b5-1 |
| Jul 1, 2026 (view filing)4:05 PM ET | Jun 29-30 | 2 days | Evans John M.CEO | SSale | −50.0K | $34.90 | −$1.75M | −4.6%1.05M after | 4 lots10b5-1 |
| Jun 29, 2026 (view filing) | Jun 25-26 | 4 days | FMR LLC10% Owner, Other: See Remark 1 | SSale | −284.9K | $35.24 | −$10.0M | −25.0%854.6K after | 2 lots |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Evans John M.CEO | SSale | −30.1K | $24.58 | −$739.3K | −2.8%1.05M after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Simon AmyChief Medical Officer | SSale | −6.70K | $24.58 | −$164.7K | −6.1%102.7K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Cavanagh Bethany JSVP, Finance and Treasurer | SSale | −3.24K | $24.58 | −$79.7K | −6.0%51.2K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Bellon ChristineChief Legal Officer | SSale | −5.96K | $24.58 | −$146.4K | −5.1%109.7K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 1 | 5 daysLate | Ciaramella GiuseppePresident | SSale | −11.8K | $24.58 | −$290.3K | −5.1%218.4K after | 10b5-1 |
| Apr 1, 2026 (view filing) | Mar 30-31 | 2 days | Evans John M.CEO | SSale | −50.0K | $22.57 | −$1.13M | −4.8%986.7K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Beam Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 12,609,002 | $432.7M | 0.02% | +156,803+1.3% | Added |
| Farallon Capital Management, L.L.C. | 10,236,396 | $351.3M | 2.06% | +101,700+1.0% | Added |
| ARK Investment Management LLCSuperinvestorARK Invest | 10,234,862 | $351.3M | 2.28% | −1,898,571−15.6% | Reduced |
| Banque Cantonale Vaudoise | 10,000 | $343.0M | 0.05% | 00.0% | Unchanged |
| BlackRock, Inc. | 8,997,542 | $308.8M | 0.00% | +509,973+6.0% | Added |
| State Street Corp | 5,827,122 | $200.0M | 0.01% | +127,857+2.2% | Added |
| Vanguard Portfolio Management LLC | 4,921,259 | $168.9M | 0.01% | +350,462+7.7% | Added |
| Vanguard Capital Management LLC | 4,599,437 | $157.9M | 0.00% | +222,063+5.1% | Added |
| ARCH Venture Management, LLC | 4,540,132 | $155.8M | 14.16% | 00.0% | Unchanged |
| Sumitomo Mitsui Trust Holdings, Inc. | 3,455,043 | $118.6M | 0.07% | −370,542−9.7% | Reduced |